Description
CT-7001 is a selective inhibitor of CDK7.
CT-7001
Product ID C760001
Cas No. 1805833-75-3
Purity ≥99%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1805833-75-3 |
|---|---|
| Purity | ≥99% |
| Formula | C22H30N6O |
| Formula Wt. | 394.52 |
| IUPAC Name | (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol |
| Synonym | Samuraciclib: ICEC0942 |
| Appearance | White to off white powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Ainscow E, Leishman A, Sullivan E, et al. Abstract 4834: CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers. Cancer Res. 2018;78(13_Supplement):4834.
Coombes C, Howell S, Krebs M, et al. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Cancer Res. 2022;82(4_Supplement):GS3-10.
Constantin T, Varela-Carver A, Greenland K, et al. The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337. PMID: 37036563.